Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2012

View Archived Issues

Rilotumumab does not improve efficacy of combination therapy in prostate cancer trial

Cixutumumab and ramucirumab studied in metastatic castration-resistant prostate cancer

FDA grants orphan drug status to Del Mar Pharmaceuticals product

Magnetic resonance techniques detect metabolic biomarker of low-grade glioma

Intellect Neurosciences provides pipeline update

Novo Nordisk completes phase I trial of novel oral insulin

Prima BioMed begins enrollment in CANVAS study

Merck KGaA claims new ALK5 inhibitors

Brazilian university patents new products with anticancer potential

Bayer Schering designs novel activators of soluble guanylate cyclase

OGX-427 shows signs of efficacy in phase II trial

Phase II trial assesses RO-4929097 in prostate cancer

Alpharadin available through new expanded access program

Pfizer designs novel liver X receptor modulators

Phase II GFT-505 study meets all efficacy objectives

Clinuvel Pharmaceuticals files MAA for erythropoietic protoporphyria treatment

Novel beta1-adrenoceptor ligands synthesized in U.K.

Novel PI3K inhibitors disclosed by Novartis

FDA accepts IND for Ziopharm product

FDA lifts partial clinical hold on hepatitis C therapy

FDA advisory committee sets date to review Marqibo NDA

Biogen Idec and Sobi release details of revised hemophilia program agreement

Oryzon choses drug candidate to begin preclinical testing for Huntington's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...